Amyotrophic lateral sclerosis behavior test
Best insight from top research papers
Amyotrophic lateral sclerosis (ALS) can manifest with cognitive and behavioral impairments. Several studies have focused on assessing cognitive and behavioral changes in ALS patients. The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) is a tool used to evaluate these impairments. It has been used to study the frequency and clinical characteristics of ALS variants with cognitive and behavioral impairments . Another screening tool, the ALS Cognitive Behavioral Screen (ALS-CBS), has been developed to assess cognitive and behavioral dysfunctions in ALS patients. Normative data for the Italian version of ALS-CBS have been generated, making it a useful tool for screening frontotemporal spectrum dysfunctions in ALS patients . Additionally, a behavior-based, automated, and quantitative drug screening system has been established using a Caenorhabditis elegans model of ALS. This model has been used to test the efficacy of various neuroprotective compounds in improving motor deficits and axonal degeneration . Overall, these studies highlight the importance of assessing cognitive and behavioral impairments in ALS patients and provide tools for screening and evaluating these impairments.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
7 Citations | The paper discusses the validation and implementation of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) in a Norwegian population. It does not mention a specific behavior test for amyotrophic lateral sclerosis (ALS). |
21 Citations | The paper describes a behavior-based drug screening system using a Caenorhabditis elegans model of motor neuron disease, but it does not specifically mention an amyotrophic lateral sclerosis behavior test. |
17 Citations | The paper mentions the Amyotrophic Lateral Sclerosis Cognitive Behavioral Screen (ALS-CBS), which includes a behavioral subscale (ALS-CBSbi) administered to caregivers to assess behavioral changes in ALS patients. |
| The paper mentions the use of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS) to assess cognitive and behavioral changes in patients with amyotrophic lateral sclerosis (ALS). |
Related Questions
What is amyotrophic lateral sclerosis?5 answersAmyotrophic lateral sclerosis (ALS), also known as motor neurone disease or Lou Gehrig's disease, is a progressive neurodegenerative disorder affecting the motor system. It leads to the degeneration of both upper and lower motor neurons in the brain and spinal cord, resulting in muscle weakness, atrophy, spasticity, and eventually paralysis. The exact cause of sporadic ALS is unknown, but familial cases have been linked to mutations in over 30 genes. Pathological processes central to ALS include protein instability, RNA processing perturbations, and disruptions in homeostasis, leading to protein aggregation, mitochondrial disturbances, and axonal transport issues. Despite no identified risk factors or family history in most cases, treatments aim to manage symptoms and improve quality of life.
Amyotrophic Lateral Sclerosis demographics5 answersAmyotrophic Lateral Sclerosis (ALS) demographics vary across different populations. In the Chicago and Detroit area, the crude incidence rates of ALS from 2009 to 2011 were 1.44, 1.53, and 1.73 cases per 100,000 person-years respectively. In an ALS multidisciplinary clinic, it was observed that spinal-onset ALS was more common in males and had an earlier onset. The National ALS Registry estimated the prevalence of ALS in the United States in 2017 to be 5.5 per 100,000 population, with a mean case count of 24,821 and an upper-bound estimate of 31,843 cases. In Finland, the crude incidence of ALS was 4.2/100,000 person-years in Southwestern Finland and 5.6/100,000 person-years in North Karelia, with prevalences of 11.9/100,000 and 10.9/100,000 respectively. ALS risk also varies across continents, with an estimated incidence of 2.2 per 100,000 person-years in Europe, 0.89 per 100,000 person-years in East Asia, and 0.79 per 100,000 person-years in South Asia.
Amyotrophic Lateral Sclerosis (ALS)5 answersAmyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease of the motor system characterized by the selective death of upper and lower motor neurons. The cause of sporadic ALS (sALS) is unknown, but investigations of familial ALS (fALS) cases have identified over 30 genes associated with the disease. Pathological processes in ALS include conformational instability and aberrant trafficking of critical proteins, perturbations of RNA processing, and disruptions of homeostasis. Glutamate-mediated neurotoxicity and decreased capacity to handle oxidative stress have also been implicated in the degenerative process. Despite advances in understanding the disease, ALS still lacks effective cures. Riluzole and edaravone have shown some benefits in slowing disease progression and improving survival, but more targeted treatments are needed. The discovery of mutations in the SOD1 gene has led to investigations into potential therapeutic possibilities. Overall, ALS is a complex disease with multiple genetic and molecular pathways involved, making it challenging to diagnose and treat effectively.
Amyotrophic lateral sclerosis (ALS) Detection Using Deep Learning Techniques4 answersDeep learning techniques have been explored for the detection of Amyotrophic Lateral Sclerosis (ALS) using various neuroimaging modalities. One study proposed a framework called SF2Former that leverages the power of vision transformer architecture to distinguish ALS subjects from healthy controls using brain magnetic resonance imaging (MRI) data. Another study developed a non-invasive machine learning model for ALS diagnosis based on voice assessment. They used the wavelet time scattering transform and correlation-based feature selection to identify relevant features for classification, achieving an accuracy of 84.2% using support vector machine (SVM). Additionally, a framework based on Hybrid Deep Convolutional Neural Networks (HD-CNN) was presented for classifying multiple sclerosis (MS) lesions in MRI slices, achieving high accuracy for different MRI sequences. Overall, deep learning techniques show promise for ALS detection using neuroimaging and voice assessment approaches.
Amyotrophic lateral sclerosis (ALS)4 answersAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects the motor neurons in the central nervous system. The cause of ALS is largely unknown, with only 2% of cases being attributed to specific genetic mutations. The diagnosis of ALS is primarily clinical, with electrodiagnostic support, neuroimaging studies, and laboratory evaluation used to rule out alternative diagnoses. Multidisciplinary care is recommended for the management of ALS, as it has been shown to prolong survival and improve quality of life. Riluzole is the only approved disease-modifying therapy, but there are numerous symptomatic therapies under investigation. There are overlaps between ALS and frontotemporal dementia, and genetic causes have been identified in up to 15% of ALS patients. Currently, multidisciplinary care and symptomatic management are the mainstays of ALS treatment, with potential for precision medicine approaches in the future.
Amyotrophic Lateral Sclerosis (ALS). explain?4 answersAmyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness, paralysis, and ultimately death. ALS is relatively common in Finland, with high incidence and prevalence rates compared to other parts of the world. The majority of ALS cases are sporadic, with no defined cause, while a small percentage is linked to mutations in specific genes such as SOD1, TDP, FUS, c9orf72, and VAPB. Clinical trials for ALS treatment require careful design and selection of outcome measures to provide informative results. Mitochondria-endoplasmic reticulum contacts (MERCs) play a crucial role in ALS pathogenesis, with dysfunction in these structures leading to mitochondrial bioenergetic alterations and motor neuron death. Environmental exposures, such as pesticide, lead, mercury, and polychlorinated biphenyls, have been associated with an increased risk of ALS. Understanding the etiology and identifying potential therapies for ALS remains a challenge, but advancements in research and clinical trials offer hope for improved outcomes and quality of life for ALS patients.